126 related articles for article (PubMed ID: 7505231)
21. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Kiriyama I; Ogaki K; Ohba S; Nishimura T
J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant hormonal therapy: the Canadian experience.
Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Tetu B; Fradet Y; Bélanger A; Candas B
Urology; 1997 Mar; 49(3A Suppl):56-64. PubMed ID: 9123738
[TBL] [Abstract][Full Text] [Related]
25. Workshop summary: hormonal suppression in the neoadjuvant setting and advanced disease.
Schulman CC; Debruyne FM; Ekman P; Labrie F
Eur Urol; 1993; 24 Suppl 2():61-3. PubMed ID: 8262127
[TBL] [Abstract][Full Text] [Related]
26. Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.
Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Têtu B; Fradet Y; Candas B
Cancer Surv; 1995; 23():149-56. PubMed ID: 7621455
[TBL] [Abstract][Full Text] [Related]
27. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
[TBL] [Abstract][Full Text] [Related]
28. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer.
Aprikian AG; Fair WR; Reuter VE; Sogani P; Herr H; Russo P; Sheinfeld J
Br J Urol; 1994 Nov; 74(5):630-6. PubMed ID: 7530128
[TBL] [Abstract][Full Text] [Related]
29. [Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
Hachiya T; Kobayashi K; Ichinose T; Ishida H; Okada K
Nihon Hinyokika Gakkai Zasshi; 1997 Nov; 88(11):936-44. PubMed ID: 9423307
[TBL] [Abstract][Full Text] [Related]
30. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.
Dalkin BL; Ahmann FR; Nagle R; Johnson CS
J Urol; 1996 Apr; 155(4):1357-60. PubMed ID: 8632574
[TBL] [Abstract][Full Text] [Related]
31. [Neoadjuvant endocrine therapy prior to nerve-sparing radical prostatectomy in patients with stage T2 prostatic cancer].
Ueda T; Nakatsu H; Isaka S; Shimazaki J
Nihon Hinyokika Gakkai Zasshi; 1995 Jul; 86(7):1266-71. PubMed ID: 7637243
[TBL] [Abstract][Full Text] [Related]
32. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant flutamide monotherapy for locally confined prostate cancer.
Yoshimura K; Sumiyoshi Y; Hashimura T; Ueda T; Kamiryo Y; Yamamoto A; Arai Y
Int J Urol; 2003 Apr; 10(4):190-5. PubMed ID: 12657097
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
35. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
[TBL] [Abstract][Full Text] [Related]
37. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.
Köllermann J; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Hopfenmüller W; Helpap B
Urology; 2003 Sep; 62(3):476-80. PubMed ID: 12946750
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
39. [The role of neoadjuvant treatment prior to radical prostatectomy].
Sassine AM; Schulman C
Acta Urol Belg; 1992; 60(3):61-71. PubMed ID: 1492635
[TBL] [Abstract][Full Text] [Related]
40. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
